Lia Danelishvili
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lia Danelishvili has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Luiz E. Bermudez
Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA
33 shared publications Martin Wu
Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, Oregon 97331,1 Department of Microbiology, Oregon State University, Corvallis, Oregon 97331,2 Molecular and Cellular Biology Program, Center for Gene Research and Biotechnology, Oregon State University, Corvallis, Oregon 973313
6 shared publicationsLuiz E. Bermudez
Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, USA
5 shared publications- Rebecca Vande Voorde
Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA
4 shared publications Yoshitaka Yamazaki
Department of Infectious Diseases and Laboratory Medicine, School of Medicine, Shinshu University, Matsumoto, Japan
4 shared publications- Carlos Adriano M. Silva
Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331, USA
3 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 743
A Trehalose-Based Phenotypic Screen Identifies Candidate Inhibitors of Mycobacterium tuberculosis Recycling Pathway
Background/Objectives: Phenotypic drug tolerance, distinct from genetic resistance, allows Mycobacterium tuberculosis (Mtb) to survive prolonged antibiotic exposure and contributes to treatment failure and relapse. The trehalose recycling pathway, mediated by the LpqY-SugABC transporter, has been implicated as a metabolic “escape” mechanism that sustains Mtb viability under antibiotic and nutrient-limiting stress, making it an attractive target for adjunctive, tolerance-breaking therapeutics. Methods and Results: Here, we conducted a high-throughput phenotypic screen of 50,000 compounds from chemically diverse libraries, using a carbon source-restricted assay that forces Mtb to rely on trehalose uptake for growth, to identify small-molecule inhibitors of this pathway. This approach yielded 23 confirmed hits in Mtb, spanning several chemical scaffolds, including thioureas, propanamides, benzamides, and carboxamides. Using an isogenic set of Mtb wild-type, LpqY-SugABC transposon knockout, and complemented strains, we confirmed that the genetic loss of transporter loss reproduces accelerated killing by isoniazid, rifampicin, and bedaquiline, but not moxifloxacin, and that loss of trehalose recycling sensitizes mycobacteria to oxidative stress. Using orthogonal functional assays, fluorescent trehalose probe (FITC-tre) uptake inhibition and H2O2 hypersensitization, thiourea-containing compounds emerged as the candidates most consistent with transporter-specific activity, phenocopying the effects of genetic LpqY-SugABC loss, while biochemical assays against recombinant trehalase (Rv2402) excluded downstream enzymatic inhibition as their mechanism of action. In addition, several hits potentiated rifampicin-mediated killing of intracellular Mtb in THP-1 macrophages, in some cases reducing bacterial burden below levels achieved by monotherapy. Conclusions: These findings indicate that the trehalose recycling pathway is functionally druggable by small molecules identified through unbiased phenotypic screening and nominate thiourea- and propanamide-based scaffolds as priority candidates for further mechanistic characterization, including direct target-engagement studies, and optimization as adjunctive anti-tuberculosis agents targeting drug-tolerant Mtb populations.
- 31 July 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 743
Open AccessA Trehalose-Based Phenotypic Screen Identifies Candidate Inhibitors of Mycobacterium tuberculosis Recycling Pathway
Background/Objectives: Phenotypic drug tolerance, distinct from genetic resistance, allows Mycobacterium tuberculosis (Mtb) to survive prolonged antibiotic exposure and contributes to treatment failure and relapse. The trehalose recycling pathway, mediated by the LpqY-SugABC transporter, has been implicated as a metabolic “escape” mechanism that sustains Mtb viability under antibiotic and nutrient-limiting stress, making it an attractive target for adjunctive, tolerance-breaking therapeutics. Methods and Results: Here, we conducted a high-throughput phenotypic screen of 50,000 compounds from chemically diverse libraries, using a carbon source-restricted assay that forces Mtb to rely on trehalose uptake for growth, to identify small-molecule inhibitors of this pathway. This approach yielded 23 confirmed hits in Mtb, spanning several chemical scaffolds, including thioureas, propanamides, benzamides, and carboxamides. Using an isogenic set of Mtb wild-type, LpqY-SugABC transposon knockout, and complemented strains, we confirmed that the genetic loss of transporter loss reproduces accelerated killing by isoniazid, rifampicin, and bedaquiline, but not moxifloxacin, and that loss of trehalose recycling sensitizes mycobacteria to oxidative stress. Using orthogonal functional assays, fluorescent trehalose probe (FITC-tre) uptake inhibition and H2O2 hypersensitization, thiourea-containing compounds emerged as the candidates most consistent with transporter-specific activity, phenocopying the effects of genetic LpqY-SugABC loss, while biochemical assays against recombinant trehalase (Rv2402) excluded downstream enzymatic inhibition as their mechanism of action. In addition, several hits potentiated rifampicin-mediated killing of intracellular Mtb in THP-1 macrophages, in some cases reducing bacterial burden below levels achieved by monotherapy. Conclusions: These findings indicate that the trehalose recycling pathway is functionally druggable by small molecules identified through unbiased phenotypic screening and nominate thiourea- and propanamide-based scaffolds as priority candidates for further mechanistic characterization, including direct target-engagement studies, and optimization as adjunctive anti-tuberculosis agents targeting drug-tolerant Mtb populations.
- Open Access
- 18 June 2026
- Vol. 14, 9
Phage Therapy for a Refractory and Multidrug-resistant Equine Surgical Site Infection.
A 14-year-old American Quarter Horse mare developed a refractory deep surgical site infection following emergency celiotomy for acute right dorsal large colon displacement with 180° volvulus. Initial cultures revealed a high-burden polymicrobial infection with Escherichia coli and Enterococcus faecium, associated with delayed healing, and later followed by multidrug-resistant Pseudomonas aeruginosa, further limiting therapeutic options. Phage therapy was initiated using a customized lytic phage cocktail administered topically on a daily basis over a 35-day period, with cocktail composition guided by daily wound culture results. Phage therapy markedly reduced colony-forming units of targeted pathogens and promoted progressive healing. Wound microbial communities varied during treatment, demonstrating selective pathogen control while preventing residual populations from recolonizing the tissue. By the time of hospital discharge, the wound surface area had decreased by more than 85%, and the body wall had healed without evidence of acute herniation. This case highlights the feasibility, safety, and clinical potential of adaptive phage therapy for managing refractory multidrug-resistant equine wound infections.
- 18 June 2026
- Vol. 14, 9
Open AccessPhage Therapy for a Refractory and Multidrug-resistant Equine Surgical Site Infection.
A 14-year-old American Quarter Horse mare developed a refractory deep surgical site infection following emergency celiotomy for acute right dorsal large colon displacement with 180° volvulus. Initial cultures revealed a high-burden polymicrobial infection with Escherichia coli and Enterococcus faecium, associated with delayed healing, and later followed by multidrug-resistant Pseudomonas aeruginosa, further limiting therapeutic options. Phage therapy was initiated using a customized lytic phage cocktail administered topically on a daily basis over a 35-day period, with cocktail composition guided by daily wound culture results. Phage therapy markedly reduced colony-forming units of targeted pathogens and promoted progressive healing. Wound microbial communities varied during treatment, demonstrating selective pathogen control while preventing residual populations from recolonizing the tissue. By the time of hospital discharge, the wound surface area had decreased by more than 85%, and the body wall had healed without evidence of acute herniation. This case highlights the feasibility, safety, and clinical potential of adaptive phage therapy for managing refractory multidrug-resistant equine wound infections.
- Open Access
- 13 February 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1753740
Phage isolation and functional characterization reveal strong antibiofilm activity against Pseudomonas aeruginosa in a cystic fibrosis sputum model
Pseudomonas aeruginosa is an opportunistic pathogen that forms persistent biofilms in the lungs of cystic fibrosis and other chronic pulmonary disease patients, contributing to antibiotic tolerance, recurrent infection, and clinical decline. The rise of multidrug-resistant P. aeruginosa underscores the urgent need for alternative therapies. Bacteriophages (phages) offer a powerful therapeutic approach by directly lysing bacteria, diminishing biofilm structures, and overcoming mechanisms that limit antibiotic efficacy. In this study, a library of 61 distinct P. aeruginosa phages was isolated and screened against 64 clinical isolates, identifying eight with broad host range and high lytic activity. These phages, including PA-319, PA-575, and PA-711, effectively prevented P. aeruginosa colonization on A549 human lung epithelial cells, inhibited bacterial biofilm formation as well as compromised established biofilms, surpassing the effects of high-concentration antibiotics. Genomic and transmission electron microscopy analyses revealed functional heterogeneity, including nucleus-forming and non-nucleus-forming jumbo phages and depolymerase-encoding genes. Our phage library provides a valuable resource for advancing research, developing combinatorial phage therapies, and optimizing treatment strategies against chronic, drug-resistant P. aeruginosa infections.
- 13 February 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1753740
Open AccessPhage isolation and functional characterization reveal strong antibiofilm activity against Pseudomonas aeruginosa in a cystic fibrosis sputum model
Pseudomonas aeruginosa is an opportunistic pathogen that forms persistent biofilms in the lungs of cystic fibrosis and other chronic pulmonary disease patients, contributing to antibiotic tolerance, recurrent infection, and clinical decline. The rise of multidrug-resistant P. aeruginosa underscores the urgent need for alternative therapies. Bacteriophages (phages) offer a powerful therapeutic approach by directly lysing bacteria, diminishing biofilm structures, and overcoming mechanisms that limit antibiotic efficacy. In this study, a library of 61 distinct P. aeruginosa phages was isolated and screened against 64 clinical isolates, identifying eight with broad host range and high lytic activity. These phages, including PA-319, PA-575, and PA-711, effectively prevented P. aeruginosa colonization on A549 human lung epithelial cells, inhibited bacterial biofilm formation as well as compromised established biofilms, surpassing the effects of high-concentration antibiotics. Genomic and transmission electron microscopy analyses revealed functional heterogeneity, including nucleus-forming and non-nucleus-forming jumbo phages and depolymerase-encoding genes. Our phage library provides a valuable resource for advancing research, developing combinatorial phage therapies, and optimizing treatment strategies against chronic, drug-resistant P. aeruginosa infections.
- Open Access
- 5 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Phage-mediated TLR2 signaling attenuates intracellular Mycobacterium abscessus survival in macrophages
The incidence of pulmonary infections caused by M. abscessus (MAB) is on rise globally. Despite susceptible infections, long-term, and combinational treatment, patients respond to MAB therapy only partially with low success rates. In recent years, therapeutic phages have been used in combination with antibiotics to enhance treatments for patients suffering with drug-resistant, chronic, and disseminated mycobacterial infections with favorable clinical outcomes. While phages are commonly recognized for their antimicrobial role through direct lysis of bacteria, expanding body of literature, describing phage interactions with the immune system, indicates that the therapeutic impact of phage may not solely hinge on lytic activity but also on stimulating innate immune responses. In this study, we aimed to uncover phages that work synergistically with macrophage cellular mechanisms, enhancing phagocyte-mediated reduction of intracellular MAB. We discovered phages stimulating TLR2 signaling associated with NLRP3 inflammasome activation, resulting in substantial attenuation of the intracellular pathogen growth. We also uncovered a new phenomenon of intracellular elimination of MAB through fusion of lytic phage vacuoles with bacterial phagosomes. This process is driven by a cellular mechanism triggered by phage exposure to phagocytic cells. New therapeutic characteristics of phage, described in this study, will contribute to future phage-based therapeutic interventions.
- 5 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessPhage-mediated TLR2 signaling attenuates intracellular Mycobacterium abscessus survival in macrophages
The incidence of pulmonary infections caused by M. abscessus (MAB) is on rise globally. Despite susceptible infections, long-term, and combinational treatment, patients respond to MAB therapy only partially with low success rates. In recent years, therapeutic phages have been used in combination with antibiotics to enhance treatments for patients suffering with drug-resistant, chronic, and disseminated mycobacterial infections with favorable clinical outcomes. While phages are commonly recognized for their antimicrobial role through direct lysis of bacteria, expanding body of literature, describing phage interactions with the immune system, indicates that the therapeutic impact of phage may not solely hinge on lytic activity but also on stimulating innate immune responses. In this study, we aimed to uncover phages that work synergistically with macrophage cellular mechanisms, enhancing phagocyte-mediated reduction of intracellular MAB. We discovered phages stimulating TLR2 signaling associated with NLRP3 inflammasome activation, resulting in substantial attenuation of the intracellular pathogen growth. We also uncovered a new phenomenon of intracellular elimination of MAB through fusion of lytic phage vacuoles with bacterial phagosomes. This process is driven by a cellular mechanism triggered by phage exposure to phagocytic cells. New therapeutic characteristics of phage, described in this study, will contribute to future phage-based therapeutic interventions.
- Open Access
- 7 February 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (2) , 225
Discovery of Biofilm-Inhibiting Compounds to Enhance Antibiotic Effectiveness Against M. abscessus Infections
Background/Objectives: Mycobacterium abscessus (MAB) is a highly resilient pathogen that causes difficult-to-treat pulmonary infections, particularly in individuals with cystic fibrosis (CF) and other underlying conditions. Its ability to form robust biofilms within the CF lung environment is a major factor contributing to its resistance to antibiotics and evasion of the host immune response, making conventional treatments largely ineffective. These biofilms, encased in an extracellular matrix, enhance drug tolerance and facilitate metabolic adaptations in hypoxic conditions, driving the bacteria into a persistent, non-replicative state that further exacerbates antimicrobial resistance. Treatment options remain limited, with multidrug regimens showing low success rates, highlighting the urgent need for more effective therapeutic strategies. Methods: In this study, we employed artificial sputum media to simulate the CF lung environment and conducted high-throughput screening of 24,000 compounds from diverse chemical libraries to identify inhibitors of MAB biofilm formation, using the Crystal Violet (CV) assay. Results: The screen established 17 hits with ≥30% biofilm inhibitory activity in mycobacteria. Six of these compounds inhibited MAB biofilm formation by over 60%, disrupted established biofilms by ≥40%, and significantly impaired bacterial viability within the biofilms, as confirmed by reduced CFU counts. In conformational assays, select compounds showed potent inhibitory activity in biofilms formed by clinical isolates of both MAB and Mycobacterium avium subsp. hominissuis (MAH). Key compounds, including ethacridine, phenothiazine, and fluorene derivatives, demonstrated potent activity against pre- and post-biofilm conditions, enhanced antibiotic efficacy, and reduced intracellular bacterial loads in macrophages. Conclusions: This study results underscore the potential of these compounds to target biofilm-associated resistance mechanisms, making them valuable candidates for use as adjuncts to existing therapies. These findings also emphasize the need for further investigations, including the initiation of a medicinal chemistry campaign to leverage structure–activity relationship studies and optimize the biological activity of these underexplored class of compounds against nontuberculous mycobacterial (NTM) strains.
- 7 February 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (2) , 225
Open AccessDiscovery of Biofilm-Inhibiting Compounds to Enhance Antibiotic Effectiveness Against M. abscessus Infections
Background/Objectives: Mycobacterium abscessus (MAB) is a highly resilient pathogen that causes difficult-to-treat pulmonary infections, particularly in individuals with cystic fibrosis (CF) and other underlying conditions. Its ability to form robust biofilms within the CF lung environment is a major factor contributing to its resistance to antibiotics and evasion of the host immune response, making conventional treatments largely ineffective. These biofilms, encased in an extracellular matrix, enhance drug tolerance and facilitate metabolic adaptations in hypoxic conditions, driving the bacteria into a persistent, non-replicative state that further exacerbates antimicrobial resistance. Treatment options remain limited, with multidrug regimens showing low success rates, highlighting the urgent need for more effective therapeutic strategies. Methods: In this study, we employed artificial sputum media to simulate the CF lung environment and conducted high-throughput screening of 24,000 compounds from diverse chemical libraries to identify inhibitors of MAB biofilm formation, using the Crystal Violet (CV) assay. Results: The screen established 17 hits with ≥30% biofilm inhibitory activity in mycobacteria. Six of these compounds inhibited MAB biofilm formation by over 60%, disrupted established biofilms by ≥40%, and significantly impaired bacterial viability within the biofilms, as confirmed by reduced CFU counts. In conformational assays, select compounds showed potent inhibitory activity in biofilms formed by clinical isolates of both MAB and Mycobacterium avium subsp. hominissuis (MAH). Key compounds, including ethacridine, phenothiazine, and fluorene derivatives, demonstrated potent activity against pre- and post-biofilm conditions, enhanced antibiotic efficacy, and reduced intracellular bacterial loads in macrophages. Conclusions: This study results underscore the potential of these compounds to target biofilm-associated resistance mechanisms, making them valuable candidates for use as adjuncts to existing therapies. These findings also emphasize the need for further investigations, including the initiation of a medicinal chemistry campaign to leverage structure–activity relationship studies and optimize the biological activity of these underexplored class of compounds against nontuberculous mycobacterial (NTM) strains.
- Open Access
- 27 October 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (11) , 1009
Discovery of Mycobacterium avium subsp. paratuberculosis Lytic Phages with Extensive Host Range Across Rapid- and Slow-Growing Pathogenic Mycobacterial Species
Background/Objectives: Developing interventions for Johne’s disease, which focuses on controlling Mycobacterium avium subsp. paratuberculosis (MAP) in contaminated environments by treating infected cows and preventing transmission from diseased animals, is a critical priority. Bacteriophage (phage) therapy, an emerging biological intervention, offers a promising alternative for the treatment and management of MAP infections. Methods: In this study, we generated an MAP-specific lytic phage library aimed at characterizing the therapeutic potential of phages under environmental and biological conditions that mimic those encountered in infected cattle such as ruminal fluid, milk, colostrum, and the bovine intestinal epithelium, a key site of MAP colonization and, later, transmission. Results: Our library contains a diverse collection of phages that have demonstrated robust lytic activity against MAP. The host range of these phages was thoroughly assessed, revealing that several isolates produce clear plaques on a range of MAP strains, as well as other pathogenic non-tuberculous mycobacterial (NTM) species and M. tuberculosis strains. This broad host range expands the therapeutic potential of the phage collection, positioning it as a potential cross-species antimicrobial tool. In vitro tests under conditions replicating the rumen, milk, and colostrum environments show that selected phages maintain stability and lytic efficacy, even in the presence of complex biological fluids. Furthermore, a subset of these phages was capable of preventing MAP colonization and invasion in cultured bovine epithelial cells, suggesting their potential for direct prophylactic application in cattle. Conclusions. Our collection of MAP phages represents a valuable source that can be developed into probiotic-like preparations, offering a cost-effective solution for prophylaxis and control of Johne’s disease.
- 27 October 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (11) , 1009
Open AccessDiscovery of Mycobacterium avium subsp. paratuberculosis Lytic Phages with Extensive Host Range Across Rapid- and Slow-Growing Pathogenic Mycobacterial Species
Background/Objectives: Developing interventions for Johne’s disease, which focuses on controlling Mycobacterium avium subsp. paratuberculosis (MAP) in contaminated environments by treating infected cows and preventing transmission from diseased animals, is a critical priority. Bacteriophage (phage) therapy, an emerging biological intervention, offers a promising alternative for the treatment and management of MAP infections. Methods: In this study, we generated an MAP-specific lytic phage library aimed at characterizing the therapeutic potential of phages under environmental and biological conditions that mimic those encountered in infected cattle such as ruminal fluid, milk, colostrum, and the bovine intestinal epithelium, a key site of MAP colonization and, later, transmission. Results: Our library contains a diverse collection of phages that have demonstrated robust lytic activity against MAP. The host range of these phages was thoroughly assessed, revealing that several isolates produce clear plaques on a range of MAP strains, as well as other pathogenic non-tuberculous mycobacterial (NTM) species and M. tuberculosis strains. This broad host range expands the therapeutic potential of the phage collection, positioning it as a potential cross-species antimicrobial tool. In vitro tests under conditions replicating the rumen, milk, and colostrum environments show that selected phages maintain stability and lytic efficacy, even in the presence of complex biological fluids. Furthermore, a subset of these phages was capable of preventing MAP colonization and invasion in cultured bovine epithelial cells, suggesting their potential for direct prophylactic application in cattle. Conclusions. Our collection of MAP phages represents a valuable source that can be developed into probiotic-like preparations, offering a cost-effective solution for prophylaxis and control of Johne’s disease.
- Open Access
- 6 May 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (5) , 1379
Understanding the Phage–Host Interaction Mechanism toward Improving the Efficacy of Current Antibiotics in Mycobacterium abscessus
Pulmonary infections caused by Mycobacterium abscessus (MAB) have been increasing in incidence in recent years, leading to chronic and many times fatal infections due to MAB’s natural resistance to most available antimicrobials. The use of bacteriophages (phages) in clinics is emerging as a novel treatment strategy to save the lives of patients suffering from drug-resistant, chronic, and disseminated infections. The substantial research indicates that phage–antibiotic combination therapy can display synergy and be clinically more effective than phage therapy alone. However, there is limited knowledge in the understanding of the molecular mechanisms in phage–mycobacteria interaction and the synergism of phage–antibiotic combinations. We generated the lytic mycobacteriophage library and studied phage specificity and the host range in MAB clinical isolates and characterized the phage’s ability to lyse the pathogen under various environmental and mammalian host stress conditions. Our results indicate that phage lytic efficiency is altered by environmental conditions, especially in conditions of biofilm and intracellular states of MAB. By utilizing the MAB gene knockout mutants of the MAB_0937c/MmpL10 drug efflux pump and MAB_0939/pks polyketide synthase enzyme, we discovered the surface glycolipid diacyltrehalose/polyacyltrehalose (DAT/PAT) as one of the major primary phage receptors in mycobacteria. We also established a set of phages that alter the MmpL10 multidrug efflux pump function in MAB through an evolutionary trade-off mechanism. The combination of these phages with antibiotics significantly decreases the number of viable bacteria when compared to phage or antibiotic-alone treatments. This study deepens our understanding of phage–mycobacteria interaction mechanisms and identifies therapeutic phages that can lower bacterial fitness by impairing an antibiotic efflux function and attenuating the MAB intrinsic resistance mechanism via targeted therapy.
- 6 May 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (5) , 1379
Open AccessUnderstanding the Phage–Host Interaction Mechanism toward Improving the Efficacy of Current Antibiotics in Mycobacterium abscessus
Pulmonary infections caused by Mycobacterium abscessus (MAB) have been increasing in incidence in recent years, leading to chronic and many times fatal infections due to MAB’s natural resistance to most available antimicrobials. The use of bacteriophages (phages) in clinics is emerging as a novel treatment strategy to save the lives of patients suffering from drug-resistant, chronic, and disseminated infections. The substantial research indicates that phage–antibiotic combination therapy can display synergy and be clinically more effective than phage therapy alone. However, there is limited knowledge in the understanding of the molecular mechanisms in phage–mycobacteria interaction and the synergism of phage–antibiotic combinations. We generated the lytic mycobacteriophage library and studied phage specificity and the host range in MAB clinical isolates and characterized the phage’s ability to lyse the pathogen under various environmental and mammalian host stress conditions. Our results indicate that phage lytic efficiency is altered by environmental conditions, especially in conditions of biofilm and intracellular states of MAB. By utilizing the MAB gene knockout mutants of the MAB_0937c/MmpL10 drug efflux pump and MAB_0939/pks polyketide synthase enzyme, we discovered the surface glycolipid diacyltrehalose/polyacyltrehalose (DAT/PAT) as one of the major primary phage receptors in mycobacteria. We also established a set of phages that alter the MmpL10 multidrug efflux pump function in MAB through an evolutionary trade-off mechanism. The combination of these phages with antibiotics significantly decreases the number of viable bacteria when compared to phage or antibiotic-alone treatments. This study deepens our understanding of phage–mycobacteria interaction mechanisms and identifies therapeutic phages that can lower bacterial fitness by impairing an antibiotic efflux function and attenuating the MAB intrinsic resistance mechanism via targeted therapy.
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S15
Abstract 1580: Understanding the Mechanism of Phage-Mycobacteria Interaction
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S15
Open AccessAbstract 1580: Understanding the Mechanism of Phage-Mycobacteria Interaction
- Open Access
- 11 February 2023
- Published by Hindawi Limited in Cellular Microbiology
- Vol. 2023, 1-14
Mycobacterium avium Infection of Multinucleated Giant Cells Reveals Association of Bacterial Survival to Autophagy and Cholesterol Utilization
Mycobacterium avium subsp. hominissuis (M. avium) is an opportunistic environmental pathogen that typically infects patients with existing lung conditions such as cystic fibrosis or COPD. Pulmonary M. avium infection generates peribronchial granulomas that contain infected macrophages and multinucleated giant cells (MGCs). While granuloma formation with MGCs is a common feature of mycobacterial infection, the role of MGCs within the granulomas as well as in the host-pathogen interaction is poorly understood. To shed light on the role of MGCs, we established a novel in vitro model utilizing THP-1 cells stimulated with a combination of IFN-γ and TNF-α. In this study, we show that MGCs can take up M. avium, which replicates intracellularly before leaving the cell. Bacteria that escape the MGC exhibit a highly invasive phenotype, which warrants further evaluation. Characterization of MGCs with transmission electron microscopy revealed an accumulation of cytoplasmic lipid droplets, autophagic activity, and multiple nuclei. Autophagy markers are upregulated in both uninfected and infected MGCs early in infection, measured by RT-qPCR analysis of Beclin-1 and LC3. Inhibition of autophagy with siRNA significantly reduced M. avium survival significantly in THP-1 macrophages. Depletion of host cholesterol and sphingomyelin in MGCs also resulted in decreased survival of M. avium. These processes potentially contribute to the formation of a supportive intracellular environment for the pathogen. Collectively, our results suggest that M. avium is adapted to replicate in MGCs and utilize them as a springboard for local spread.
- 11 February 2023
- Published by Hindawi Limited in Cellular Microbiology
- Vol. 2023, 1-14
Open AccessMycobacterium avium Infection of Multinucleated Giant Cells Reveals Association of Bacterial Survival to Autophagy and Cholesterol Utilization
Mycobacterium avium subsp. hominissuis (M. avium) is an opportunistic environmental pathogen that typically infects patients with existing lung conditions such as cystic fibrosis or COPD. Pulmonary M. avium infection generates peribronchial granulomas that contain infected macrophages and multinucleated giant cells (MGCs). While granuloma formation with MGCs is a common feature of mycobacterial infection, the role of MGCs within the granulomas as well as in the host-pathogen interaction is poorly understood. To shed light on the role of MGCs, we established a novel in vitro model utilizing THP-1 cells stimulated with a combination of IFN-γ and TNF-α. In this study, we show that MGCs can take up M. avium, which replicates intracellularly before leaving the cell. Bacteria that escape the MGC exhibit a highly invasive phenotype, which warrants further evaluation. Characterization of MGCs with transmission electron microscopy revealed an accumulation of cytoplasmic lipid droplets, autophagic activity, and multiple nuclei. Autophagy markers are upregulated in both uninfected and infected MGCs early in infection, measured by RT-qPCR analysis of Beclin-1 and LC3. Inhibition of autophagy with siRNA significantly reduced M. avium survival significantly in THP-1 macrophages. Depletion of host cholesterol and sphingomyelin in MGCs also resulted in decreased survival of M. avium. These processes potentially contribute to the formation of a supportive intracellular environment for the pathogen. Collectively, our results suggest that M. avium is adapted to replicate in MGCs and utilize them as a springboard for local spread.
- Open Access
Identification of Small Molecule Inhibitors against Mycobacteria in Activated Macrophages
Mycobacterial pathogens are intrinsically resistant to many available antibiotics, making treatment extremely challenging, especially in immunocompromised individuals and patients with underlying and chronic lung conditions. Even with lengthy therapy and the use of a combination of antibiotics, clinical success for non-tuberculous mycobacteria (NTM) is achieved in fewer than half of the cases. The need for novel antibiotics that are effective against NTM is urgent. To identify such new compounds, a whole cell high-throughput screen (HTS) was performed in this study. Compounds from the Chembridge DIVERSet library were tested for their ability to inhibit intracellular survival of M. avium subsp. hominissuis (MAH) expressing dtTomato protein, using fluorescence as a readout. Fifty-eight compounds were identified to significantly inhibit fluorescent readings of MAH. In subsequent assays, it was found that treatment of MAH-infected THP-1 macrophages with 27 of 58 hit compounds led to a significant reduction in intracellular viable bacteria, while 19 compounds decreased M. abscessus subsp. abscessus (Mab) survival rates within phagocytic cells. In addition, the hit compounds were tested in M. tuberculosis H37Ra (Mtb) and 14 compounds were found to exhibit activity in activated THP-1 cells. While the majority of compounds displayed inhibitory activity against both replicating (extracellular) and non-replicating (intracellular) forms of bacteria, a set of compounds appeared to be effective exclusively against intracellular bacteria. The efficacy of these compounds was examined in combination with current antibiotics and survival of both NTM and Mtb were evaluated within phagocytic cells. In time-kill dynamic studies, it was found that co-treatment promoted increased bacterial clearance when compared with the antibiotic or compound group alone. This study describes promising anti-NTM and anti-Mtb compounds with potential novel mechanisms of action that target intracellular bacteria in activated macrophages.
Open AccessIdentification of Small Molecule Inhibitors against Mycobacteria in Activated Macrophages
Mycobacterial pathogens are intrinsically resistant to many available antibiotics, making treatment extremely challenging, especially in immunocompromised individuals and patients with underlying and chronic lung conditions. Even with lengthy therapy and the use of a combination of antibiotics, clinical success for non-tuberculous mycobacteria (NTM) is achieved in fewer than half of the cases. The need for novel antibiotics that are effective against NTM is urgent. To identify such new compounds, a whole cell high-throughput screen (HTS) was performed in this study. Compounds from the Chembridge DIVERSet library were tested for their ability to inhibit intracellular survival of M. avium subsp. hominissuis (MAH) expressing dtTomato protein, using fluorescence as a readout. Fifty-eight compounds were identified to significantly inhibit fluorescent readings of MAH. In subsequent assays, it was found that treatment of MAH-infected THP-1 macrophages with 27 of 58 hit compounds led to a significant reduction in intracellular viable bacteria, while 19 compounds decreased M. abscessus subsp. abscessus (Mab) survival rates within phagocytic cells. In addition, the hit compounds were tested in M. tuberculosis H37Ra (Mtb) and 14 compounds were found to exhibit activity in activated THP-1 cells. While the majority of compounds displayed inhibitory activity against both replicating (extracellular) and non-replicating (intracellular) forms of bacteria, a set of compounds appeared to be effective exclusively against intracellular bacteria. The efficacy of these compounds was examined in combination with current antibiotics and survival of both NTM and Mtb were evaluated within phagocytic cells. In time-kill dynamic studies, it was found that co-treatment promoted increased bacterial clearance when compared with the antibiotic or compound group alone. This study describes promising anti-NTM and anti-Mtb compounds with potential novel mechanisms of action that target intracellular bacteria in activated macrophages.